Biocon services

Syngene is a publicly listed subsidiary whose core capabilities include highly effective problem-solving and scientific innovation, allied to a clear commitment to safety, quality, and operating excellence. It takes an integrated approach to the disciplines of discovery, development and manufacturing of novel molecules to ensure a quality project delivery on time, every time – all with a single-minded commitment to turning clients’ ideas into meaningful innovation.

We are rapidly growing our development, regulatory and clinical expertise, along with world class manufacturing capabilities, to break existing oligopolies and make therapies affordable to patients globally. Biocon Biologics’ state-of-the-art manufacturing facilities are certified by various regulatory agencies from developed and emerging markets. With an unwavering commitment to quality, the Biocon Biologics has made significant investments in commercial scale, globally compliant manufacturing facilities across diverse technology platforms spanning insulin analogs, monoclonal antibodies and other recombinant proteins. We continue to expand our infrastructure in a capital-efficient, modular way.

Biocon Biologics’ Research and Development organisation is fully integrated to develop high-quality biosimilars (recombinant insulins, monoclonal antibodies and other protein therapeutics) that can be registered in highly regulated markets like USA, Europe and Japan.

Branded Formulations present an opportunity to provide patients in India with world class treatment options that are effective and affordable. Our Branded Formulations business has positioned us as a leading biologics-led, specialty products company focused on chronic therapy areas. We have built considerable brand equity with doctors and patients over the years through our affordable and differentiated portfolio in challenging disease spaces. A combination of products, patients and physician support programs have enabled us to achieve market leadership in the therapeutic areas of diabetology, oncology, immunology and critical care.

Bicara Therapeutics, a wholly owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates our development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.